Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (201-210 of 251) with videos related to

Pageof 26
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|February 6, 2021
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysisAndrea Casadei-Gardini, Mario Scartozzi, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2019
Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarkerHeejung Chae, Deokhoon Kim, Changhoon Yoo, et al.
Investigational New Drugs|December 2, 2017
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus CisplatinHyungwoo Cho, Changhoon Yoo, Kyu-Pyo Kim, et al.
Journal for Immunotherapy of Cancer|April 9, 2026
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabYu Sato, Takahiro Kodama, Kazuki Maesaka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract CancerYeong Hak Bang, Choong-Kun Lee, Kyunghye Bang, et al.
Seminars in Oncology|June 10, 2025
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world populationFrancesco Vitiello, Toshifumi Tada, Goki Suda, et al.
Journal of Hepatology|June 5, 2025
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancerFlorian Castet, Carles Fabregat-Franco, John Bridgewater, et al.
Cancer Medicine|February 22, 2023
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantationKyunghye Bang, Andrea Casadei-Gardini, Changhoon Yoo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 8, 2022
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activationEunsil Sung, Minkyung Ko, Ju-Young Won, et al.
Cancer Research and Treatment|December 14, 2021
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking GroupShinkyo Yoon, Miso Kim, Yong Sang Hong, et al.
Pageof 26

Showing results (201-210 of 251) with videos related to

Sort By:
Pageof 26
Liver International : Official Journal of the International Association for the Study of the Liver|February 6, 2021
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysisAndrea Casadei-Gardini, Mario Scartozzi, Toshifumi Tada, et al.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2019
Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarkerHeejung Chae, Deokhoon Kim, Changhoon Yoo, et al.
Investigational New Drugs|December 2, 2017
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus CisplatinHyungwoo Cho, Changhoon Yoo, Kyu-Pyo Kim, et al.
Journal for Immunotherapy of Cancer|April 9, 2026
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabYu Sato, Takahiro Kodama, Kazuki Maesaka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract CancerYeong Hak Bang, Choong-Kun Lee, Kyunghye Bang, et al.
Seminars in Oncology|June 10, 2025
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world populationFrancesco Vitiello, Toshifumi Tada, Goki Suda, et al.
Journal of Hepatology|June 5, 2025
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancerFlorian Castet, Carles Fabregat-Franco, John Bridgewater, et al.
Cancer Medicine|February 22, 2023
Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantationKyunghye Bang, Andrea Casadei-Gardini, Changhoon Yoo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 8, 2022
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activationEunsil Sung, Minkyung Ko, Ju-Young Won, et al.
Cancer Research and Treatment|December 14, 2021
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking GroupShinkyo Yoon, Miso Kim, Yong Sang Hong, et al.
Pageof 26